GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Beryl Drugs Ltd (BOM:524606) » Definitions » Enterprise Value

Beryl Drugs (BOM:524606) Enterprise Value : ₹137.1 Mil (As of May. 08, 2025)


View and export this data going back to 1994. Start your Free Trial

What is Beryl Drugs Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Beryl Drugs's Enterprise Value is ₹137.1 Mil. Beryl Drugs's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was ₹9.1 Mil. Therefore, Beryl Drugs's EV-to-EBIT ratio for today is 15.07.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Beryl Drugs's Enterprise Value is ₹137.1 Mil. Beryl Drugs's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was ₹21.5 Mil. Therefore, Beryl Drugs's EV-to-EBITDA ratio for today is 6.37.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Beryl Drugs's Enterprise Value is ₹137.1 Mil. Beryl Drugs's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was ₹198.7 Mil. Therefore, Beryl Drugs's EV-to-Revenue ratio for today is 0.69.

EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Beryl Drugs's Enterprise Value is ₹137.1 Mil. Beryl Drugs's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was ₹0.0 Mil. Therefore, Beryl Drugs's EV-to-FCF ratio for today is .


Beryl Drugs Enterprise Value Historical Data

The historical data trend for Beryl Drugs's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beryl Drugs Enterprise Value Chart

Beryl Drugs Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 66.90 78.22 99.22 101.36 197.47

Beryl Drugs Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 112.14 197.47 162.25 234.75 183.35

Competitive Comparison of Beryl Drugs's Enterprise Value

For the Drug Manufacturers - Specialty & Generic subindustry, Beryl Drugs's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Beryl Drugs's Enterprise Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Beryl Drugs's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Beryl Drugs's Enterprise Value falls into.


;
;

Beryl Drugs Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Beryl Drugs's Enterprise Value for the fiscal year that ended in Mar. 2024 is calculated as

Beryl Drugs's Enterprise Value for the quarter that ended in Dec. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Beryl Drugs  (BOM:524606) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Beryl Drugs's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=137.112/9.096
=15.07

Beryl Drugs's current Enterprise Value is ₹137.1 Mil.
Beryl Drugs's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹9.1 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Beryl Drugs's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=137.112/21.541
=6.37

Beryl Drugs's current Enterprise Value is ₹137.1 Mil.
Beryl Drugs's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹21.5 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Beryl Drugs's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=137.112/198.652
=0.69

Beryl Drugs's current Enterprise Value is ₹137.1 Mil.
Beryl Drugs's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹198.7 Mil.

4. EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow.

Beryl Drugs's EV-to-FCF for today is:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=137.112/0
=

Beryl Drugs's current Enterprise Value is ₹137.1 Mil.
Beryl Drugs's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Beryl Drugs Enterprise Value Related Terms

Thank you for viewing the detailed overview of Beryl Drugs's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Beryl Drugs Business Description

Traded in Other Exchanges
N/A
Address
133, Kanchan Bagh, Ground Floor, Indore, MP, IND, 452001
Beryl Drugs Ltd is a pharmaceutical company principally engaged in the manufacturing and marketing of allopathic pharmaceutical preparations. It also provides contract manufacturing services and veterinary products. It offers manufacturing options for product requirements like small-volume injectables in liquid form, small-volume injectables in dry powder form, eye and ear drops, intravenous fluids in poly pack and glass bottles, and veterinary medicines. The company earns the majority of its revenue from the sale of Bulk Drugs.

Beryl Drugs Headlines

No Headlines